COMPARISON OF UPFRONT ARAT THERAPY AND CAB THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A RETROSPECTIVE MULTICENTER STUDY

被引：0
|
作者：
Shiraishi, Yusuke
Tobe, Taisuke
Ueki, Hideto
Suzuki, Kotaro
Hara, Takuto
Terakawa, Tomoaki
Teishima, Jun
Nakano, Yuzo
Miyake, Hideaki
Fujisawa, Masato
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP60-10
引用
收藏
页码：E1003 / E1004
页数：2
相关论文
共 50 条
  • [41] Editorial Comment to Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
    Sakamoto, Shinichi
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 370 - 370
  • [42] Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer
    Condon, Benjamin
    Liskaser, Grace
    Thangasamy, Isaac A.
    Murphy, Declan G.
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 620 - 622
  • [43] Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer: A multicenter study.
    Urabe, Fumihiko
    Kimura, Takahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 118 - 118
  • [44] Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review
    Kyriakopoulos, Christos E.
    Liu, Glenn
    CANCER JOURNAL, 2016, 22 (05): : 322 - 325
  • [45] Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer REPLY
    Garcia, Jorge A.
    Sweeney, Christopher
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03): : 287 - 287
  • [46] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [47] Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study
    Urabe, Fumihiko
    Muramoto, Katsuki
    Yanagisawa, Takafumi
    Fukuokaya, Wataru
    Mori, Keiichiro
    Tashiro, Kojiro
    Katsumi, Kota
    Takahashi, Hidetsugu
    Yoshihara, Kentaro
    Miyajima, Keiichiro
    Imai, Yu
    Iwatani, Kosuke
    Kayano, Sotaro
    Igarashi, Taro
    Murakami, Masaya
    Tsuzuki, Shunsuke
    Shimomura, Tatsuya
    Yamada, Hiroki
    Miki, Jun
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (11) : 1248 - 1255
  • [48] New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer
    Alekseev, B. Ya
    ONKOUROLOGIYA, 2019, 15 (03): : 89 - 101
  • [49] A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
    Sung, W. W.
    Choi, H. C.
    Luk, P. H.
    So, T. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1326 - S1326
  • [50] A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
    Sung, Winnie W. Y.
    Choi, Horace C. W.
    Luk, Peter H. Y.
    So, Tsz Him
    FRONTIERS IN ONCOLOGY, 2021, 11
12345